FDA Raises Concern Over Opioid Abuse Related to Alkermes' Schizophrenia Drug

Shares of Alkermes climbed more than 6% Wednesday after the U.S. Food and Drug Administration (FDA) released its assessment of the company’s schizophrenia and bipolar drug ahead of an advisory committee meeting scheduled for Friday.